Back to results
US 12,533,409 B2Granted
Compositions and methods for targeting mutant RAS
AssigneeThe Trustees of the University of Pennsylvania
InventorsAdham Bear, Robert Vonderheide, Gerald Linette, Beatriz Carreno
Life of this patent
Estimating the term…
Abstract
This invention relates to compositions and methods of treating cancer associated with mutant RAS. In certain aspects, the invention relates to antigenic RAS peptide fragments and T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types.
Claims8
A composition comprising a T-cell receptor (TCR) that specifically binds to a mutant RAS (mRAS) peptide in the context of an HLA molecule selected from the group consisting of:
- HLA-A*02:01, HLA-A*03:01, HLA-A*11:01, and HLA-B*07:02;
- wherein
- a) when the HLA molecule is HLA-A*02:01, the HLA-A*02:01 comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOs:
- 1-4;
- b) when the HLA molecule is HLA-A*03:01, the HLA-A*03:01 comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOs:
- 5-12;
- c) when the HLA molecule is HLA-A*11:01, the HLA-A*11:01 comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOs:
- 5-12;
- or
- d) when the HLA molecule is HLA-B*07:02, the HLA-B*07:02 comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOs:
- 13-16.
8 more elements
Dependencies are inferred from the claim text.